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Abstract: Aneurysmal rupture accounts for the majority of subarachnoid hemorrhage and is re-
sponsible for most cerebrovascular deaths with high mortality and morbidity. Initial hemorrhage
severity and secondary brain injury due to early brain injury and delayed cerebral ischemia are the
major determinants of outcomes after aneurysmal subarachnoid hemorrhage. Several therapies have
been explored to prevent these secondary brain injury processes after aneurysmal subarachnoid
hemorrhage with limited clinical success. Experimental and clinical studies have shown a neuropro-
tective role of certain anesthetics in cerebrovascular disorders including aneurysmal subarachnoid
hemorrhage. The vast majority of aneurysmal subarachnoid hemorrhage patients require general
anesthesia for surgical or endovascular repair of their aneurysm. Given the potential impact certain
anesthetics have on secondary brain injury after SAH, appropriate selection of anesthetics may
prove impactful on overall outcome of these patients. This narrative review focuses on the available
evidence of anesthetics and their adjuvants in neurovascular protection in aneurysmal subarachnoid
hemorrhage and discusses current impact on clinical care and future investigative directions.
Keywords: anesthetics; anesthetic adjuvants; neurovascular protection; aneurysmal subarachnoid
hemorrhage; early brain injury; delayed cerebral ischemia; neurological outcomes
1. Introduction
The incidence of hemorrhagic stroke in the general population accounts for approxi-
mately 20% of all the strokes, with 5% due to subarachnoid hemorrhage (SAH) [1]. The
morbidity and mortality remains high for this patient population. For aneurysmal SAH,
30% of patients die [2] and 50% of survivors have long-term cognitive deficits that preclude
their return to work [3]. The two most important determinants of outcome after SAH are
initial hemorrhage severity and secondary brain injury due to early brain injury (EBI) and
delayed cerebral ischemia (DCI). EBI occurs in 12% of patients, develops 1–3 days after
SAH and is characterized by blood–brain barrier (BBB) disruption, neuronal cell death,
neuroinflammation and cerebral edema [4]. DCI occurs in ~30% of patients, develops
4–12 days after SAH and is characterized by large artery vasospasm, distal autoregulatory
dysfunction, microvessel thrombosis and cortical spreading depression [5]. Though many
strategies to prevent EBI and DCI have been explored over the years, none have proven
efficacious. New therapies are desperately needed to treat these conditions.
In recent decades, many experimental studies have shown a strong neuroprotective
effect of certain anesthetics on EBI and DCI. Some of these studies have also shown an im-
pact on mortality and neurological outcome. A more limited set of clinical studies suggest
that certain anesthetics may have a protective effect in SAH patients. The vast majority of
aneurysmal SAH patients will be exposed to anesthetics either in the operating room for
surgical repair of the aneurysm, the interventional neuroradiology suite for endovascular
treatment of the aneurysm, or in the neurointensive care unit for sedation after the initial
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hemorrhagic insult. Given the potential protective effects of certain anesthetic agents and
their adjuvants, choice of anesthetic technique may prove critical in the management of
SAH patients. The aim of the present review is to critically analyze the available evidence
implicating a role of certain anesthetics and their adjuvants in neurovascular protection in
aneurysmal SAH.
2. Methodology
Literature search for this review was performed for the following inhalational anesthet-
ics (desflurane, sevoflurane, isoflurane, halothane, Xenon, Argon), intravenous anesthetics
(propofol, etomidate, barbiturates, ketamine) and adjuvants for anesthetics (clonidine,
dexmedetomidine, benzodiazepines and opioids) in relation to aneurysmal SAH until
April 2021. Literature search was conducted in PubMed and EMBASE database. Clinical
and experimental studies focusing on the anesthetic effects on EBI, DCI and neurobehav-
ioral outcomes after aneurysmal SAH are included. Studies with abstracts only, languages
other than English, with additional treatments on top of anesthetics, studies which did
not directly assess one of the components of EBI or DCI and invitro studies were not
included. Following search criterions were used for the review: Inhalational anesthetics
(isoflurane, desflurane, sevoflurane, halothane, Xenon, Argon) and aneurysmal subarach-
noid hemorrhage, intravenous anesthetics (propofol, etomidate, barbiturates, ketamine)
and aneurysmal subarachnoid hemorrhage and adjuvants (clonidine, dexmedetomidine,
benzodiazepines and opioids) and aneurysmal subarachnoid hemorrhage. A total of
655 articles were screened and 40 articles met the inclusion criteria which forms the basis
of this narrative review (Figure 1).
Figure 1. Flow diagram of search strategies.
3. EBI after SAH
EBI occurs 1–3 days after SAH and it is an independent risk factor for poor outcomes.
It consists of several elements such as blood–brain barrier disruption, cell death, neuroin-
flammation and cerebral edema [4]. Though the incidence of EBI is less, it is increasingly
recognized as one of the important contributors of significant morbidity and mortality after
SAH. After the initial aneurysmal rupture causing SAH, there is a peak rise in intracra-
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nial pressure (ICP) leading to a transient global cerebral ischemia. The transient global
cerebral ischemia and the hemoglobin in the subarachnoid space exacerbates the cerebral
injury by activating several pathways such as apoptosis, inflammation and oxidative stress
which may contribute to the blood–brain barrier disruption eventually causing cerebral
edema [6]. Currently, there are no targeted therapies available to treat EBI and the primary
management is focused on ICP control and cerebral perfusion pressure optimization [7].
Here, we review the available preclinical (Table 1) and clinical (Table 2) evidence from the
literature on the anesthetic/adjuvants effects on EBI after SAH.




Altay et al. reported a series of complementary studies examining the protective effect
of brief exposure to isoflurane anesthesia on SAH-induced EBI [8–10] They showed in
an endovascular perforation mouse model of SAH that exposure to 2% isoflurane for 1hr
when started 1 h post-SAH attenuated brain water content, decreased neuronal apoptosis
and improved neurological score at 24 hr [8]. These protective effects, however, were
not seen at 72 h [8]. Through a series of pharmacologic experiments, this EBI protection
was causally linked to the sphingosine pathway. In this study, isoflurane exposure was
shown to increase sphingosine kinase 1 (SphK1) expression, Akt phosphorylation and
decreased cleaved caspase-3 after SAH. Administration of specific SphK antagonist, N,
N dimethyl sphingosine (DMS) and a S1P1-3 receptor antagonist, VPC23019 eliminated
the beneficial effects of isoflurane against EBI indicating that isoflurane’s neuroprotective
effect was mediated through sphingosine related pathway. Subsequent studies by the
same authors validated the protective effect of brief exposure to 2% isoflurane (but not
1% isoflurane) against EBI, including attenuation of blood–brain barrier disruption9 and
reduction in neuroinflammation [10]. In both these studies, isoflurane’s EBI protection was
reversed by DMS and VPC23019 representing the involvement of sphingosine pathway in
isoflurane’s neuroprotection.
Clinical Studies
A recent prospective study [11] examined the effects of multiple anesthetics (isoflu-
rane, sevoflurane, desflurane, propofol) at different time points (baseline, one hour after
anesthetic induction, one hour after end of anesthesia) on cerebrospinal fluid (CSF) and
serum caspase-3 levels in SAH patients undergoing aneurysmal coiling/clipping. A sig-
nificant reduction in CSF caspase-3 levels and an increase in serum caspase-3 levels was
noticed at one hour after anesthetic exposure, which was consistent with all anesthetics.
The authors concluded that anesthetics may have a transient resuscitative role during acute
brain injury after SAH by potentially reducing caspase-3 expression/activity in the brain
injury, as reflected by a reduction in caspase-3 levels in CSF.
4.1.2. Sevoflurane
Experimental Studies
Sevoflurane exposure in an endovascular perforation mouse model of SAH was shown
to protect against EBI. The authors administering varying concentrations of sevoflurane
(1.5%, 3%, 4.5%) one hour after SAH induction at three different treatment durations
(30, 60, 90 min) showed that 1.5% sevoflurane for 60 min as well as 3% for 30 or 60 min
provided significant protection against EBI including improved neurological scores, less
cerebral edema and neuronal apoptosis [12]. These results indicate proper sevoflurane
dosing is critical towards achieving maximal EBI protection, with higher concentration
(4.5%) and prolonged exposure (90 min) resulting in loss of neurovascular protection. No
data was provided regarding underlying mechanism for the demonstrated EBI protection.
A subsequent study by Altay et al., [13] comparing the effects of 3% sevoflurane vs 2%
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isoflurane in a mouse endovascular perforation SAH model showed that both anesthetics
attenuated SAH-induced EBI to a similar level and also improved neurological function
at 24 h. Though the mechanism beyond the anesthetic protection was not explored in the
study, the authors noted that both anesthetics upregulated sphingosine kinase-1 protein
expression suggesting a possible involvement of the Sphk1 related pathway in anesthetic
induced EBI protection. A recent study by Beck-Schimmer et al. comparing sevoflurane vs
propofol sedation in a rat endovascular perforation SAH model provided evidence that
sevoflurane sedation post SAH attenuated cerebral edema [14]. While a causal mechanism
behind sevoflurane’s protection had not been explored in the study, authors speculated that
sevoflurane might attenuate cerebral edema by stabilizing the adherens junction protein
beta catenin.
4.2. Inert or Noble Gases
Experimental Studies
Helium, neon, argon, krypton and xenon are considered inert or noble gases, which
at standard temperature and pressure have very low anesthetic activity. Xenon is the
only inert gas that can be used as an anesthetic at atmospheric pressure, though it is not
clinically used due to its expense and technical complexities. Hollig et al. [15] showed that
rats exposed to a mixture of 50 vol% argon/50 vol% oxygen (O2) for 1 h beginning 1 h after
SAH induction in an endovascular perforation model maintains animal body weight and
reduces mortality when compared to control. However, neuroscore and cerebral edema did
not differ between groups. The authors noted a significant increase in hypoxia inducible
factor—1 alpha (HIF-1α) and hemeoxygenase—1 (HO-1) expression by argon exposure,
24 h after SAH and speculated that argon’s neuroprotective effect was mediated through
HIF-1α induced HO-1 expression. Veldeman et al [16] showed that rats exposed to Xenon
(50 vol% O2/50 vol% Xe) for 1 h initiated at 1 h post SAH in an endovascular perforation
model protected against hippocampal damage including reduced neuronal damage and
microglial activity in the CA3 and dentate gyrus. A subsequent study administering Xenon
to rats through echogenic liposomes (Xe-ELIP) (600 µL per animal, 10 mg lipid/mL) 30 min
after SAH in an endovascular perforation model reduced hemorrhage volume and neuronal
cell death, improved neurological function and decreased mortality [17]. In all studies
examining inert or noble gases, no data were provided to causally relate any underlying




Shi et al. reported that rats administered intravenous propofol (10 vs 50 mg/kg)
beginning at 2 h and repeated 12 h after SAH in an endovascular perforation model signifi-
cantly reduced cerebral edema, blood–brain barrier breakdown and improved neurological
scores. A dose dependent effect of propofol was reported in the study with higher propofol
dose (50 mg/kg) being more effective in improving neurological scores, reducing brain
edema and BBB breakdown and lower dose of propofol (10 mg/kg) was more effective
in attenuating the inflammation. Propofol was shown to exert its neuroprotective effect
through activation of anti-oxidative nuclear factor erythroid-related factor 2 signaling, inhi-
bition of pro-inflammatory Nuclear factor-kappa B (NF-kB) pathway and downregulating
aquaporin, matrix metalloproteinase and cyclooxygenase-2 [18]. A follow up study by
the same authors showed that intraperitoneal administration of propofol 50 mg/kg at 2 h
and repeated at 12 h after SAH in a rat endovascular perforation model reduced cerebral
edema, blood–brain barrier permeability and improved neurological scores. Propofol’s EBI
protection in this study was reversed by LY294002, a specific inhibitor of Phosphatidyli-
nositol 3-kinase/Akt (PI3K/Akt) signaling pathway, suggesting a possible involvement of
PI3K/Akt pathway in propofol’s protection [19].
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Table 1. Anesthetics and adjuvants in early brain injury (EBI) after SAH in experimental studies.
References AnestheticAgent/Adjuvants Species Model Pathway Effects
[8] Isoflurane Mice Endovascularperforation SphK, S1P1 ↑
Reduced brain water content, decreased
neuronal apoptosis, improved
neurological score.
[9] Isoflurane Mice Endovascularperforation SphK, S1P1 ↑
Improved neurological score, brain edema,
BBB permeability and prevented the
decrease in expressions of tight junction
(occludin, JAM-A and claudin-5) and
adherens junction (VE- cadherin) proteins.
[10] Isoflurane Mice Endovascularperforation SphK, S1P1 ↑
Improved neurological score, brain edema,
BBB permeability and decreased
neuroinflammation (↓ MPO, iba-1, IL-1β,
TNF-α, P-selectin, ICAM-1, p-JNK and
COX-2).
[12] Sevoflurane Mice Endovascularperforation -
Improved neurological scores, reduced
cerebral edema and apoptosis.
[13] Sevoflurane/Isoflurane Mice Endovascularperforation
SphK 1 ↑, COX-2 ↓,
Caspase -3 ↓
Both anesthetics attenuated cerebral
edema, cell death, improved
neurobehavioral function.
[14] Sevoflurane/Propofol Rat Endovascularperforation
Stabilizing Beta
Catenin Sevoflurane attenuated cerebral edema.
[15] Argon Rat Endovascularperforation HIF-1 α ↑, HO-1 ↑
Reduced mortality and functional
outcome improved as measured by the
weight of the animals.
[16] Xenon Rat Endovascularperforation -
Hippocampal protection, reduction in
microglial activity.
[17] Xenon Rat Endovascularperforation -
reduced hematoma volume, prevented
neuronal cell death, improved
neurological function and decreased the
mortality and morbidity.
[18] Propofol Rat Endovascularperforation
Nrf2 ↑, NF-kB ↓,
AQP4 ↓, MMP-9 ↓,
COX-2
Reduces cerebral edema, BBB
permeability, improves Neuroscore.
[19] Propofol Rat Endovascularperforation ↑ PI3K/Akt
Reduces cerebral edema, BBB
permeability, improves Neuroscore.
[21] Dexmedetomidine Rat Endovascularperforation ERK ↑
Reduced cerebral edema, BBB
permeability, improved neuroscore.
[22] Dexmedetomidine Rat Endovascularperforation
TLR4/ NF-kB ↓,
NLRP3 ↓
Reduced cerebral edema, BBB
permeability, neuronal apoptosis, inhibits
neuroinflammation and improves
neuroscore.
[23] Salvinorin A Rat Endovascularperforation ↑ PI3K/Akt
Attenuated cerebral edema and neuronal
apoptosis.
↑ = Activation/Increase/elevation, ↓ = Inhibition/blockade/decrease, EBI = early brain injury, BBB = blood–brain barrier, OGD =
oxygen glucose deprivation, SphK = Sphingosine kinase, S1P1 = Sphingosine-1-phosphate receptor, MPO = myeloperoxidase, iba-1 =
Ionized calcium binding adaptor molecule-1, p-JNK = phospho-c-Jun N-terminal kinase, IL-1β = interleukin-1 beta, TNF-α = tumor
necrosis factor-alpha, ICAM-1 = intercellular adhesion molecule-1, COX-2 = cyclooxygenase-2, HIF-1 = hypoxia inducible factor, Nrf2 =
Nuclearfactorerythroid-relatedfactor2, NF-kB = Nuclear factor-kappa B, AQP4 = aquaporin, MMP-9 = matrix metalloproteinase, ERK =
extracellular signal—regulated kinase, PI3K/Akt = Phosphatidylinositol 3-kinase/Akt, TLR4 = Toll-like receptor 4, NLRP3 = nucleotide-
binding oligomerization domain-like receptor family pyrin domain-containing 3.
Clinical Studies
A prospective study where patients receiving either propofol or sevoflurane for anes-
thetic maintenance after temporary clip removal during intracranial aneurysm proce-
dure observed a decrease in serum markers of oxidative stress (hydroxyl radicals and
8-isoprostane) and an increase in serum antioxidant levels (gamma-tocopherol and super-
oxide dismutase activity) in patients treated with propofol vs. sevoflurane. This effect
was noticed from immediate postoperative period to seven days post procedure. In ad-
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dition, cognitive function was better in the propofol treated group when measured by
Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA)
scores up to 7 days after surgery. The authors proposed that propofol post-conditioning
may protect against oxidative stress injury by enhancing antioxidation and decreasing free
radical injury [20].
Table 2. Anesthetics and adjuvants in early brain injury (EBI) after SAH in patients.
References Anesthetic Agent/Adjuvants Sample Size Effects
[11] Isoflurane, Sevoflurane,Desflurane, Propofol. 44
CSF caspase-3 levels ↓, serum caspase-3 levels ↑
at one hour after anesthetic exposure.
[20] Propofol 60
Oxidative stress is reduced (gamma-tocopherol
and SOD ↑, OH and 8-isoprostane ↓), Cognitive
function is improved.
↑ = Activation/Increase/elevation, ↓ = Inhibition/blockade/decrease, SAH =subarachnoid hemorrhage, CSF = cerebrospinal fluid, OH =




Dexmedetomidine, a highly selective alpha 2 adrenergic receptor agonist, is a sedative
with analgesic and anesthetic sparing effects. Intraperitoneal administration of dexmedeto-
midine (25 µg/kg) in rats immediately and 2 h post SAH in an endovascular perforation
model reduced cerebral edema, blood–brain barrier permeability and improved neurolog-
ical scores. Dexmedetomidine administration was also shown to increase the activated
extracellular signal-regulated kinase (ERK) after SAH. PD98095, an inhibitor of ERK acti-
vation abolished this effect and also reversed dexmedetomidine’s EBI protection causally
linking dexmedetomidine’s neuroprotection in SAH to ERK signaling pathway [21]. Sim-
ilar results were reported by Yin et al., who noted that intraperitoneal administration of
dexmedetomidine (25 µg/kg) in rats, 2 h post SAH in an endovascular perforation model
reduced cerebral edema, neuronal apoptosis, blood–brain barrier permeability, neuroin-
flammation and improved neurological scores. In this study, dexmedetomidine’s protection
against EBI was proposed to mediate via inhibition of nucleotide-binding oligomeriza-
tion domain-like receptor family pyrin domain-containing 3 inflammasome and Toll-like
receptor 4/NF-kB pathway [22].
4.4.2. Opioids
Experimental Studies
Sun et al., [23] noted that the administration of salvinorin A (a selective kappa opioid
receptor agonist) attenuated cerebral edema (as measured by the volume of the lateral
ventricle by MRI on day 3 after SAH) in a rat endovascular perforation SAH model. In
addition, authors showed that salvinorin A reduced neuronal apoptosis in hippocampus.
Through pharmacological experiments, this EBI protection of salvinorin A was linked to
PIK3/Akt pathway.
5. DCI after SAH
DCI is another important independent risk factor for poor patient outcome after
SAH. Cerebral vasospasm is an important contributor for DCI and for decades, it was
attributed to be the primary driver of poor outcomes [24] Recent evidence showing that
attenuation of cerebral vasospasm did not lead to a significant change in functional outcome
or mortality [25], indicating that the pathophysiology underlying DCI is multifactorial and
that other pathophysiological factors, which are independent of vasospasm, can contribute
to the outcome. The other contributors of DCI which are causally linked to the patient
outcomes are microvascular dysfunction, microvascular thrombosis and cortical spreading
depression.5 Some overlap between the mechanisms of EBI and DCI injury exists, such
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as the oxidative stress and inflammation. Additional mechanisms, such as increase in
procoagulant activity leading to microvessel thrombosis, are noted in DCI patients [24].
Several treatment strategies for DCI have failed in the past with only a limited success with
nimodipine [24,26]. The treatment failures may have resulted likely from targeting only a
single element of what has proven to be a multifactorial process [24,26]. Here, we review
the available preclinical (Table 3) and clinical (Table 4) evidence from the literature on the
anesthetic/adjuvants effects on DCI after SAH.




The first experimental study examining the impact of anesthetic conditioning on DCI
came from Milner et al., who exposed wild-type mice to a brief period of isoflurane anes-
thesia (2% isoflurane for 1 h) at several time points after induction of SAH via endovascular
perforation technique. They found that isoflurane conditioning initiated 15min, 1hr and
3 h (but not 6 h) after SAH significantly improved multiple elements of DCI including large
artery vasospasm, microvessel thrombosis and autoregulatory dysfunction and that this
neurovascular protection led to improved neurological outcome [27]. Through a series of
pharmacological and genetic interventions, this DCI protection was causally linked to en-
dothelial cell-derived hypoxia inducible factor—1 alpha (HIF-1α). In this study, isoflurane
was shown to modulate HIF transcriptional targets such as BCL2 Interacting Protein 3,
erythropoietin and glucose transporter 1. Genetic and pharmacologic inhibition of HIF-1α
blocked these changes and eliminated the isoflurane’s protection against SAH-induced
DCI indicating that isoflurane induced DCI protection is mediated through HIF-1α. Sub-
sequently, several additional studies have similarly shown in mouse models of SAH that
isoflurane conditioning provides protection against DCI and neurological deficits and that
this protection is HIF-1α-mediated [28–30]. More recently, Athiraman et al. [31] provided
evidence showing that a brief exposure of 2% isoflurane for one hour initiated one-hour
post SAH in a mouse endovascular perforation model attenuated neurovascular deficits
caused by SAH. In this study, isoflurane was shown to upregulate endothelial nitric oxide
synthase (eNOS) expression and the DCI protection was causally linked to eNOS through
pharmacologic and genetic interventions. In all the above-mentioned studies, concentration
of isoflurane employed for the experiments was 2%, which is a supratherapeutic dose and
not commonly used for the patients during surgical procedures. Therefore, a subsequent
study by Athiraman et al., [32] comparing three different doses of isoflurane (subanes-
thetic (0.5%), anesthetic (1%) and a supratherapeutic dose (2%)) in a mouse endovascular
perforation SAH model provided interesting observation showing that all three doses of
isoflurane afforded significant protection against SAH-induced DCI and no difference
in neurovascular protection was appreciated between three doses. No mechanism was
explored in this study. A follow up study by Liu et al. [33], elucidating the mechanism by
which isoflurane conditioning provides DCI protection, showed that isoflurane significantly
downregulated SIRT1 (silent mating type information regulation 2 homolog) expression
and co-administration of a highly selective SIRT1 inhibitor (EX-527) with isoflurane did not
block isoflurane induced DCI protection. This indicates that SIRT1 may not be involved in
the molecular cascade of isoflurane conditioning induced DCI protection. Nevertheless,
authors revalidated their initial findings showing that a brief exposure of 2% isoflurane
provided significant DCI protection.
6.1.2. Sevoflurane and Desflurane
Clinical Studies
The first hint that inhalational anesthetics may provide protection against vasospasm
and/or DCI in SAH patients came from Wang et al. [34], who examined plasma concentrations
of endothelin-1 (ET-1)—a major contributing molecule to vasospasm pathophysiology—in
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SAH patients undergoing aneurysm clipping. They found that desflurane anesthesia reduced
ET-1 levels at several different time points during aneurysm surgery as compared to
pre-induction ET-1 levels. Additional evidence that inhalational anesthetics may have
a protective effect on vasospasm came from Lee et al., who reported that SAH patients
undergoing desflurane anesthesia during aneurysm clipping suffered a lower incidence
of transcranial Doppler-evident vasospasm as compared to SAH patients undergoing
propofol anesthesia [25]. No difference in angiographic vasospasm or DCI, however,
was noted [35]. The most direct evidence to date suggesting inhalational anesthetics
provide protection against vasospasm and DCI in SAH patients came from our study
where we examined a cohort of patients who underwent inhalational anesthetic only
technique (sevoflurane or desflurane) vs. combined anesthetic technique (sevoflurane or
desflurane plus propofol) during surgical or endovascular aneurysm repair. We found
that the inhalational anesthetic only technique was associated with lower incidence of
angiographic vasospasm and that desflurane anesthesia in particular had a potential
protective effect against DCI [36]. A follow-up retrospective study by our group in a
larger cohort of SAH patients showed that inhalational anesthetic exposure reduces both
angiographic and symptomatic vasospasm [37]. However, it is important to note that no
impact on functional outcome at discharge was found in both studies as measured by
modified Rankin scale (mRS). More recently, a preliminary prospective study comparing
the effects of desflurane vs propofol on post-operative cognitive dysfunction (POCD) in
SAH patients undergoing aneurysm clipping procedure did not find a difference in the




A prospective study of SAH patients undergoing aneurysm clipping conducted by
Luo et al. examined the potential effects of propofol anesthesia on cerebral vasospasm
by measuring intra-operative levels of calcitonin gene related peptide (CGRP)—a well
described vasodilator with mechanistic links to cerebral vasospasm—during aneurysm
surgery. They found that propofol significantly reduced intraoperative CGRP levels at
several different time points, which might suggest propofol anesthesia may potentially
increase the risk of cerebral vasospasm after SAH [39]. In contradistinction, Hertle et al. [40]
provided evidence that propofol anesthesia may provide a protective effect against one
element of DCI known as cortical spreading depolarization. They performed a multicenter
observational study in brain-injured patients including those with SAH and examined
the impact of several analgesics and sedatives on cortical spreading depolarization as
measured by spreading depolarization, isoelectric spreading depolarization and spread-
ing depolarization clusters. Propofol was found to reduce the occurrence of spreading
depolarization clusters, though the underlying mechanism behind this protection was not
explored. Recently, two preliminary prospective studies examining the impact of propofol
during aneurysm clipping in SAH patients did not find an effect on cognitive function




A retrospective study conducted by Brelie et al [42] examined the effects of ketamine
vs non-ketamine sedation on the occurrence of DCI-related cerebral infarctions in ven-
tilated SAH patients. They found the rate of DCI-associated infarctions was lower in
those treated with ketamine. The postulated underlying mechanism accounting for this
potential protective effect included (1) suppression of cortical spreading depolarization,
(2) NMDA antagonism and (3) a direct vasodilatory effect. In addition, several studies
have examined the impact of ketamine on cortical spreading depression in SAH patients.
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Sakowitz et al. [43] showed in one SAH patient that ketamine inhibited spreading depo-
larization and also restored the regular pattern electrocorticographic activity. The afore-
mentioned study by Hertle et al. found that ketamine reduced the occurrence of all three
measurements of cortical spreading depolarization [40]. Additional evidence for ketamine’s
protective effect on spreading depolarizations came from Carlson et al. [44], who showed
that ketamine significantly inhibited cortical spreading depolarization over wide range of
doses (0.55 mg/kg/h–1.15 mg/kg/h) with maximum effect seen at or above 1.15 mg/kg/h.
More recently, Santol et al. [45] provided evidence showing that sedation with s-ketamine
in the mechanically ventilated SAH patients was associated with reduced incidence of
spreading depolarizations.
Table 3. Anesthetics and adjuvants in delayed cerebral ischemia (DCI) after SAH in experimental studies.
References AnestheticAgent/Adjuvants Species Model Pathway Effects
[27] Isoflurane Mice Endovascularperforation HIF-1 α ↑
Reduces large artery vasospasm,
microvessel thrombosis, autoregulatory
dysfunction and improves the
neurological outcome.
[28–30] Isoflurane Mice Endovascularperforation HIF-1 α ↑
Reduced DCI as measured by the
occurrence of new cerebral infarctions in
the MRI and improved neurobehavioral
outcome.
[31] Isoflurane Mice Endovascularperforation eNOS ↑
Attenuated large artery vasospasm and
improved neurological outcome
[32] Isoflurane Mice Endovascularperforation -
Attenuated large artery vasospasm and
improved neurological outcome




Attenuated large artery vasospasm,
microvessel thrombosis and improved
neurological outcome
[46] Clonidine Rabbit Cisterna Magnainjection SNS ↓ Reduced chronic vasospasm.
[47] Dexmedetomidine Rat Cisterna Magnainjection
MDA ↓,
SNS ↓ Reduced vasospasm and oxidative stress.
[48] Dexmedetomidine Rat Cisterna Magnainjection IL-6 ↓
Reduced vasospasm and improved
neurological function.
↑ = Activation/Increase/elevation, ↓ = Inhibition/blockade/decrease, DCI = delayed cerebral ischemia, SAH = subarachnoid hemorrhage,
ET-1 = endothelin-1, HIF-1 = hypoxia inducible factor-1, eNOS = endothelial nitric oxide synthase, SIRT1 = silent mating type information
regulation 2 homolog, SNS = sympathetic nervous system, MDA = malonialdehyde, IL-6 = interleukin.
Table 4. Anesthetics and adjuvants in delayed cerebral ischemia (DCI) after SAH in patients.
References AnestheticAgent/Adjuvants Sample Size Effects
[34] Desflurane 45 ET-1 ↓. May reduce the risk of acute cerebral vasospasm.
[35] Desflurane/Propofol 102 Less incidence of TCD-evident vasospasm with desflurane.
[36] Desflurane 157 Lower incidence of DCI.
[37] Sevoflurane/Desflurane 390 Lower incidence of angiographic vasospasm and DCI.
[38] Desflurane/Propofol 70 No effects on POCD at the time of discharge.
[39] Propofol 45 CGRP↓. May potentiate the risk of acute cerebral vasospasm.
[41] Propofol 66 No effect on cognition at time of hospital discharge.
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Table 4. Cont.
References AnestheticAgent/Adjuvants Sample Size Effects
[40] Ketamine, midazolam,propofol 31
Ketamine ↓ the occurrence of spreading depolarization’s, clusters
of spreading depolarization’s and isoelectric spreading
depolarizations. (NMDA ↓) Midazolam ↑ spreading depolarization
clusters. (GABA ↓). Propofol ↓ clusters of spreading
depolarizations.
[42] Ketamine 65
Lower incidence of non-procedural related infarctions probably
through NMDA ↓, ↓ cortical spreading depolarization and
vasodilation.
[43] Ketamine 1 NMDA ↓. Cortical spreading depolarization ↓.
[44] Ketamine 8 ↓ spreading depolarizations.
[45] Ketamine 66 ↓ spreading depolarizations.
[50] Dexmedetomidine 161 Favorable neurologic outcome at discharge as measured by mRS.
[49] Dexmedetomidine 127 No impact on vasospasm or clinical outcome at discharge asmeasured by mRS and GOS.
[51] flunitrazepam,midazolam, propofol 29
Associated with poor outcomes at 6 months after discharge as
measured by GOS.
↑ = Activation/Increase/elevation, ↓ = Inhibition/blockade/decrease, ET-1 = endothelin, TCD = transcranial Doppler, CGRP = calcitonin
gene- related peptide, GABA = Gamma- aminobutyric acid, NMDA = N-methyl- D- Aspartate, POCD = post-operative cognitive




Clonidine is a relatively nonspecific α2 adrenergic receptor agonist with sedative,
analgesic and anesthetic sparing effects. Bunc et al. showed that intramuscular adminis-
tration of a clinically relevant dose of clonidine (0.03 mg/kg) immediately after induction
of SAH and continued daily until animal sacrifice prevented basilar artery vasospasm
in a rabbit cisterna magna injection model. Though the underlying mechanism was not
specifically explored, its anti-vasospastic effect was attributed to clonidine’s ability to block
the sympathetic nervous system activity [46].
6.3.2. Dexmedetomidine
Experimental Studies
Ayoglu et al. [47] compared the effects of two different doses of dexmedetomidine
(5 and 10 µg/kg) administered intraperitoneally 1 h after SAH and repeated 24 h later in a
rat cisterna magna injection model. They found a dose-dependent effect of dexmedetomi-
dine against SAH-induced vasospasm. This DCI protection was postulated to be the result
of reduced oxidative stress and blockade of the sympathetic nervous system. Similar results
were noted by Song et al. [48], who found that 10 µg/kg dexmedetomidine administered
intraperitoneally 1 h after SAH and repeated 24 h later reduced vasospasm and improved
neurological outcome in a rat cisterna magna injection model. Given that dexmedetomidine
also reduced CSF levels of interleukin-6, the authors hypothesized that the DCI protection
was related to its anti-inflammatory action.
Clinical Studies
A recent correspondence from Esfahani et al., [49] investigating SAH patients who
received dexmedetomidine for ICU sedation did not find an association with vasospasm
protection or favorable clinical outcomes at discharge as measured by mRS and Glasgow
Outcome scale. As noted by the authors, the study was limited by small sample size,
non-standardized dexmedetomidine dosing and difference in the clinical severity between
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the compared groups. In contradistinction, Okazaki et al., [50] in their retrospective study
showed that SAH patients who received low dose of dexmedetomidine (0.01–0.20 µg/kg/h)
during the first 24 h of admission were associated with favorable neurological outcomes at
discharge as measured by mRS scale.
6.3.3. Benzodiazepines
Clinical Studies
In the Hertle et al. [40] study, the impact of a midazolam (a sedative and anxiolytic)
on cortical spreading depolarization in brain-injured patients was examined. They noted
that midazolam sedation may actually increase the occurrence of cortical spreading depo-
larization. The proposed hypothesis for this effect was GABAergic inhibition leading to
suppression of brain metabolism and exacerbation of energy dependent ion pump failure.
One other small retrospective study by Hertle et al. [51] showed that sedation with gamma
aminobutyric acid related drugs (flunitrazepam, midazolam and propofol) in the mechani-
cally ventilated SAH patients was associated with poor outcomes as measured by Glasgow
outcome scale at 6 months.
7. Summary of Anesthetics/Adjuvants and Neurovascular Protection in SAH
7.1. Inhalational Anesthetics
The most studied inhalational anesthetic in preclinical studies has been isoflurane.
Several experimental studies have shown that isoflurane provides significant protection
against both EBI and DCI after SAH [8–10,13,27–33]. To date, however, isoflurane has not
been examined in clinical studies of SAH. Sevoflurane—a commonly used inhalational
anesthetic for neurosurgical procedures—has been shown in several preclinical studies
to protect against multiple components of SAH-induced EBI such as cerebral edema
and neuronal apoptosis including improved neurological outcomes at 24 h [12–14]. No
experimental studies have yet evaluated sevoflurane’s impact on SAH-induced DCI. Finally,
though no experimental studies have thus far evaluated the impact of desflurane on SAH-
induced secondary brain injury (EBI and DCI), three clinical studies have been reported, all
of which show desflurane likely reduces the incidence of SAH-induced vasospasm [34–36].
Finally, no studies have been conducted to examine the impact of inhalational anesthetics
on the long-term neurobehavioral outcomes after SAH.
7.2. Intravenous Anesthetics
Available experimental and clinical evidence, though somewhat limited in scope,
have shown that propofol protects against SAH-induced EBI [18,19]. Whether propofol
provides protection against SAH-induced DCI, however, remains unclear. One clinical
study demonstrated a protective effect against DCI [40], while another clinical study refuted
this finding [39]. Given that propofol is one of the most commonly used intravenous
anesthetic agents for induction and maintenance during neurosurgical procedures, it
will be important to further investigate the potential protective effects of this anesthetic
agent on SAH-induced secondary brain injury. Another intravenous anesthetic with a
potential protective effect on DCI is the NMDA antagonist, ketamine. Though no preclinical
studies examining its impact in SAH have been reported, several clinical studies show
that ketamine is effective at reducing cortical spreading depression—one of the critical
components of DCI—in SAH patients [40,42–45].
7.3. Anesthetic Adjuvants
Dexmedetomidine is a highly selective centrally acting alpha-2 adrenergic agonist
that is commonly used as an adjunct to other anesthetic agents during neurosurgical
procedures. Several experimental studies show dexmedetomidine provides significant pro-
tection against both EBI and DCI following SAH [21,22,47,48]. A clinical study supports the
use of dexmedetomidine in SAH patients as it shows a favorable neurologic outcome [50]
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and another study finds no impact on the outcomes [49]. Benzodiazepines, specifically
midazolam has been shown to associate with poor outcomes in SAH patients [40,51].
8. Limitations of the Current Literature
(1) All the above-mentioned preclinical studies used male animals for their exper-
iments. Importantly, however, SAH in patients occurs more frequently in females vs.
males [52] and differences in SAH outcome between males and females have been noted in
preclinical studies [53]. It is therefore essential that future experimental studies include
female animals to address gender as a potential biologic variable. (2) The anesthetic dose
used in the majority of experimental studies may not correlate with the anesthetic dose
utilized in SAH patients. Different strains, species and the age group used in the experi-
ments further complicates this issue. (3) Several of the experimental studies did not identify
a causal mechanism for anesthetic/adjuvant induced neuroprotection in SAH, which is
critical in the development of drug therapeutics. (4) Limited clinical studies are available to
show the impact of anesthetics on secondary brain injury and long-term neurobehavioral
outcomes after SAH. These studies are further limited by their (a) retrospective nature;
(b) smaller cohort size to causally show an impact on patient outcomes; and (c) lack of
standardized measures to examine cognitive and long-term neurobehavioral outcomes.
Hence, well designed properly controlled larger randomized prospective studies are critical
in evaluating the impact of anesthetics on the secondary brain injury outcomes after SAH.
9. Concluding Remarks
A growing body of literature—both experimental and clinical—indicates certain
anesthetics likely have substantial protective effects against both EBI and DCI following
SAH [54]. From animal studies, we have learned that protection afforded by anesthetics is
multifaceted including positive effects on inflammation, blood–brain barrier breakdown,
cerebral edema, neuronal apoptosis, microvascular thrombi, autoregulatory dysfunction
and large artery vasospasm. The pleiotropic nature of the protective effects of certain
anesthetics (EBI and DCI; neurons and cerebral vessels) has a great potential for anesthetic-
based therapies to ultimately translate into robust protection against secondary brain injury
in SAH patients and improvement in overall neurological outcome. The excellent safety
profile and relative ease at which anesthetic agents can be delivered to acutely ill patients
only enhances the promise of this therapeutic approach. Studies to further elucidate the
underlying mechanisms of anesthetic-induced neurovascular protection in SAH in the
hopes of identifying novel and druggable therapeutic targets are warranted, as are clinical
studies designed to identify the most appropriate anesthetics, optimize their dosing and
rigorously test for therapeutic benefit in SAH patients.
10. Future Studies
Based on the breadth of experimental and clinical data implicating certain anesthetics
and anesthetic adjuvants with reducing EBI and DCI and improving neurological outcome
after SAH, additional studies examining the impact of these agents in SAH are warranted.
In particular, studies designed to address the following would be especially impactful:
(1) determining the differential benefit of various anesthetics on SAH outcome; (2) defining
optimal dosing and effective therapeutic window for SAH; (3) elucidating underlying
mechanisms of anesthetic-induced neurovascular protection in SAH; and (4) exploring
the impact of anesthetic treatment on long-term neurobehavioral and cognitive outcomes
after SAH.
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